Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

HELP

Helus Pharma Inc

Feb 27 • 04:00PM ET

7.35

-0.41 -5.28 %

Healthcare • Biotechnology • Canada • NASD

Peers: DFTX ATAI CMPS RLMD GHRS AVXL BTAI NBIX BHVN

| Held by: PSIL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.52	Insider Own	21.50%	Shs Outstand	49.89M	Perf Week	7.93%
Market Cap	367.79M	Forward P/E	-	EPS next Y	-2.96	Insider Trans	0.00%	Shs Float	39.28M	Perf Month	3.09%
Enterprise Value	172.66M	PEG	-	EPS next Q	-0.74	Inst Own	43.29%	Short Float	7.73%	Perf Quarter	19.12%
Income	-122.31M	P/S	-	EPS this Y	6.68%	Inst Trans	25.39%	Short Ratio	4.50	Perf Half Y	-4.17%
Sales	0.00M	P/B	1.34	EPS next Y	22.56%	ROA	-52.45%	Short Interest	3.04M	Perf YTD	-10.15%
Book/sh	5.49	P/C	1.88	EPS next 5Y	13.28%	ROE	-55.47%	52W High	9.83 -25.23%	Perf Year	-11.45%
Cash/sh	3.90	P/FCF	-	EPS past 3/5Y	31.02% -232.48%	ROIC	-44.65%	52W Low	4.81 52.81%	Perf 3Y	-65.46%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.72% 9.50%	Perf 5Y	-84.72%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-18.26%	Oper. Margin	-	ATR (14)	0.59	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.78	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.21	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	13.78	EPS Q/Q	-166.25%	SMA20	9.68%	Beta	0.82	Target Price	41.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	1.56%	Rel Volume	0.48	Prev Close	7.76
Employees	50	LT Debt/Eq	0.00	Earnings	Feb 16 BMO	SMA200	4.72%	Avg Volume	674.06K	Price	7.35
IPO	Sep 13, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-31.58% -	Trades		Volume	322,926	Change	-5.28%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-02-26	Initiated	Jefferies	Buy	$22
Mar-13-25	Initiated	Guggenheim	Buy	$35
Nov-19-21	Downgrade	Maxim Group	Buy → Hold

Feb-27-26 11:44AM	Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments (PR Newswire) -5.28%
Feb-26-26 12:07PM	Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders (PR Newswire)
Feb-24-26 09:35AM	Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity (PR Newswire) +9.51%
07:45AM	Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee (GlobeNewswire)
Feb-20-26 11:14AM	Magic Mushrooms, Hard Cash: Compass Pathways' Trial Win, Fast Raise (MarketBeat)
09:29PM	Loading…
Feb-18-26 09:29PM	Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers (Insider Monkey) +5.03%
Feb-17-26 07:30AM	Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder (GlobeNewswire) +11.00%
Feb-16-26 02:58PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Feb-13-26 07:31AM	HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-10-26 08:30AM	Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market (PR Newswire)
07:30AM	Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution (GlobeNewswire)
Jan-05-26 07:30AM	HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq (Business Wire) -6.64%
Jan-04-26 04:51PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-20-25 08:02PM	Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges (GuruFocus.com)
Oct-22-25 07:00AM	BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor (NewMediaWire)
09:00AM	Loading…
Sep-03-25 09:00AM	Morning Movers: United Therapeutics surges after TETON-2 met primary endpoint (TipRanks)
Sep-02-25 03:52AM	Cybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression Therapy (Insider Monkey) -16.58%
Aug-18-25 06:07PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Aug-13-25 05:30PM	Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results (Business Wire) -5.66%
Aug-07-25 07:30AM	Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder (Business Wire)
Aug-06-25 07:30AM	Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
Jul-20-25 07:00PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-18-25 09:55AM	Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? (Zacks)
Jul-17-25 07:30AM	Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder (Business Wire) +12.50%
Jul-16-25 09:46AM	3 High-Risk, High-Reward Stocks With Explosive Upside (MarketBeat)
Jul-01-25 11:19AM	REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures (Business Wire) +7.27%
Jun-30-25 10:03PM	Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights (Business Wire)
09:27PM	Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures (Business Wire)
Jun-25-25 04:08AM	Cybin Granted Key Patent for CYB004 DMT Program, Supports GAD Treatment Development (Insider Monkey) +5.36%
Jun-19-25 10:10AM	Trump Trade: President said to weigh possible U.S. strike against Iran (TipRanks)
09:26AM	Loading…
09:26AM	Psychedelic advocates hopeful Trump administration will support space, STAT says (TipRanks)
Jun-18-25 08:30AM	Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 (Newsfile)
Jun-13-25 07:45AM	Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics (Business Wire)
Jun-12-25 07:30AM	Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference (Business Wire)
Jun-11-25 07:30AM	Cybin to Participate in the 2025 Psychedelic Science Conference (Business Wire)
Jun-03-25 07:30AM	Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder (Business Wire)
May-22-25 07:30AM	Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 (Business Wire)
May-20-25 07:30AM	Cybin Applauds FDA Commissioner Dr. Martin Makarys Call to Accelerate and Prioritize Research on Psychedelic Therapeutics (Business Wire) -6.53%
May-15-25 07:30AM	Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder (Business Wire)
May-14-25 07:30AM	Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase (Business Wire)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks) +6.33%
May-08-25 07:30AM	Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder (Business Wire) +6.76%
May-01-25 07:30AM	Cybin to Participate at the 28th Annual Milken Institute Global Conference (Business Wire)
Apr-27-25 03:31PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Apr-25-25 11:30AM	Psychedelic: Clearmind completes clinical site initiations for AUD trial (TipRanks)
Apr-23-25 07:30AM	Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 (Business Wire)
Apr-21-25 08:00AM	Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs (Business Wire)
Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks)
Mar-04-25 09:35AM	Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
Feb-17-25 09:55AM	Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet (Zacks)
Feb-10-25 09:48PM	Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights (Business Wire)
Jan-30-25 09:55AM	Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade (Zacks)
Jan-15-25 12:07PM	Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder (Business Wire)
Jan-13-25 07:30AM	Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 (Business Wire)
Jan-09-25 05:00PM	Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 (Business Wire)
Dec-10-24 07:30AM	Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results (Business Wire)
Dec-04-24 07:30AM	Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 (Business Wire)
Nov-18-24 07:00AM	Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder (Business Wire) -8.62%
Nov-14-24 07:30AM	Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 (Business Wire)
Nov-13-24 07:30AM	Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results (Business Wire) -10.26%
Oct-31-24 07:30AM	Cybin to Participate at the 2024 Milken Institute Future of Health Summit (Business Wire)
Oct-24-24 07:30AM	Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program (Business Wire)
Oct-03-24 07:30AM	Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 (Business Wire)
Oct-01-24 07:30AM	Cybin Expands Clinical Team to Support CYB003 Phase 3 Program (Business Wire)
Sep-24-24 07:30AM	Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit (Business Wire)
Sep-19-24 05:38PM	Cybin Provides Corporate Update on Upcoming Clinical Milestones (Business Wire) +10.42% +7.24%
07:26AM	Cybin Announces Completion of Previously Announced Share Consolidation (Business Wire)
Sep-04-24 07:55AM	Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-27-24 07:01PM	Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation (Business Wire)
Aug-13-24 07:30AM	Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder (Business Wire)
Aug-08-24 07:36AM	Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights (Business Wire)
Aug-07-24 07:30AM	Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Jul-08-24 08:38AM	A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update (Newsfile)
Jun-27-24 12:00PM	What Makes Cybin Inc. (CYBN) a New Buy Stock (Zacks)
Jun-26-24 07:41AM	Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights (Business Wire)
Jun-19-24 07:30AM	Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (Business Wire)
Jun-11-24 09:35AM	Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround (Zacks) +6.83%
07:30AM	Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development (Business Wire)
May-29-24 07:30AM	Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024 (Business Wire)
May-14-24 07:30AM	Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase (Business Wire)
May-06-24 08:32AM	Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones (Business Wire) +5.14%
Apr-25-24 07:30AM	Cybin to Participate at the 27th Annual Milken Institute Global Conference (Business Wire)
Apr-18-24 07:30AM	Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry (Business Wire)
Apr-16-24 07:30AM	Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder (Business Wire)
Apr-10-24 07:30AM	Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference (Business Wire) -5.90%
Mar-19-24 11:53AM	Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million (Business Wire)
Mar-18-24 07:30AM	Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas (Business Wire)
Mar-15-24 07:30AM	Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder (Business Wire) +7.23%
Mar-14-24 07:30AM	Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design (Business Wire)
Mar-13-24 07:00AM	Announces Oversubscribed Private Placement of U.S. $150 Million (Business Wire)
06:00AM	Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder (Business Wire)
Mar-12-24 10:37PM	Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003 (Business Wire) +10.28%
Feb-27-24 07:30AM	Cybin to Present at the TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-14-24 07:45AM	Cybin Reports Third Quarter Financial Results and Recent Business Highlights (Business Wire)
Feb-07-24 07:30AM	Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program (Business Wire) -9.06%
Jan-28-24 05:02PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jan-24-24 09:00AM	How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition (PR Newswire)

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HELP

Helus Pharma Inc

Upgrade your FINVIZ experience